Delays From Clinical Manifestations to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A National Retrospective Cohort Study
Journal of the American Heart Association · 04.11.2026
DOI: 10.1161/jaha.125.048942 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the American Heart Association, online erschienen am 04.11.2026. Verfasst von Joshua D Mitchell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Amyloid Center of Excellence, Cardiovascular Division Washington University School of Medicine St Louis MO USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, life‐threatening condition. Timely and accurate diagnosis remains a challenge. We assessed time from first recorded clinical manifestation to ATTR‐CM diagnosis in the United States and characterized manifestations associated with diagnostic delays.
Methods
Retrospective analysis of US claims data (Komodo Healthcare Map, July 1, 2016–June 30, 2024). Patients were required to have ≥3 years of continuous enrollment before diagnosis.
Results
Among 7509 patients, mean age 75.9 years, 63.2% male, 54.5% White, and 28.6% Black. Patients had a median of 8 manifestations before diagnosis; median observed time from first recorded manifestation to diagnosis was 5.2 years, shorter for variant versus wild‐type ATTR‐CM (4.4 versus 5.2 years). Within 3 years before diagnosis, patients had a mean of 12.04 (95% CI, 11.75–12.35) primary care physician visits and 14.45 (95% CI, 14.10–14.80) specialists of interest visits, most commonly with cardiologists and ophthalmologists. In adjusted analyses, variant ATTR‐CM was associated with shorter time to diagnosis (β, −0.41 years [95% CI, −0.56 to −0.26]), whereas comorbidities, including hypertension (β, 0.46 years [95% CI, 0.27–0.64]), were associated with longer delays.
Conclusions
The diagnostic trajectory for ATTR‐CM can be prolonged and challenging, leading to more advanced disease at diagnosis and increased burden. Raising awareness may provide an opportunity for earlier diagnosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Amyloid Center of Excellence, Cardiovascular Division Washington University School of Medicine St Louis MO USA.
- BridgeBio Pharma, Inc. San Francisco CA USA.
- Genesis Research Group Hoboken NJ USA.
- Stanford Amyloid Center, Division of Cardiovascular Medicine Stanford University School of Medicine Stanford CA USA.
- Department of Medicine, Division of Cardiology University of Washington Seattle WA USA.
ORCID-Profile: Joshua D Mitchell, Margarita Udall, Liana Hennum, Hanh Dung Dao, Bret Zeldow, Kevin M Alexander, Richard K Cheng
Zitieren
APA
Mitchell, J. D., Udall, M., Hennum, L., Dao, H. D., Zeldow, B., Nagelhout, E., Alexander, K. M., & Cheng, R. K. (2026). Delays From Clinical Manifestations to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A National Retrospective Cohort Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.048942
Vancouver
Mitchell JD, Udall M, Hennum L, Dao HD, Zeldow B, Nagelhout E, et al. Delays From Clinical Manifestations to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A National Retrospective Cohort Study. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.048942
BibTeX
@article{Mitchell2026,
author = {Mitchell, Joshua D and Udall, Margarita and Hennum, Liana and Dao, Hanh Dung and Zeldow, Bret and Nagelhout, Elizabeth and Alexander, Kevin M and Cheng, Richard K},
title = {Delays From Clinical Manifestations to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A National Retrospective Cohort Study},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.048942}
}
EUVIMED